Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update ​ LOS ANGELES, Calif., November 12, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnolo

Event · Earnings
Original reporting
Published Nov 12, 2026, 9:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ARMP
Bullish
high confidence
Mentioned
$ARMP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ARMPBullishMed
01

Why it matters

The FDA breakthrough designation and new DoD funding reduce development risk and could catalyze share price appreciation ahead of the pivotal trial.

02

Market read

Regulatory breakthrough and funding news provide a fresh catalyst for ARMP, potentially driving short‑term upside ahead of Phase 3.

03

What to watch

The $62 M other income from convertible loan fair‑value changes may mask underlying cash‑flow challenges.

Relevance 7/10Novelty 8/10Timing: phase‑3 initiation expected in H2 2026
AlphAI · Earnings readARMP · Q3 2026 · ended 2026-09-30

Armata reports Q3 2026 net income of $54.9 million, driven by a $69.6 million non-cash gain on the convertible loan, while operating loss narrowed to $7.4 million

→Mixed quarter

The operating loss narrowed year over year and grant revenue rose, but the reported net income rests on a $69.6 million gain from the change in fair value of the convertible loan. Operating cash use for the nine months was $(19,964) thousand, and the balance sheet shows a stockholders' deficit of $(174,128) thousand with $178.2 million of combined convertible loan and term debt on the current and non-current lines.

Revenue
$3.17M
EPS · GAAP
$(0.24)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Grant and award revenue, Q3 2026 (three months ended Sep 30)GAAP$3.17M––
Research and development expenses, Q3 2026GAAP$6.83M––
General and administrative expenses, Q3 2026GAAP$3.72M––
Total operating expenses, Q3 2026GAAP$10.55M––
Operating loss, Q3 2026GAAP−$7.38M––
Interest income, Q3 2026GAAP$206K––
Interest expense, Q3 2026GAAP−$7.56M––
Change in fair value of the Convertible Loan, Q3 2026GAAP$69.59M––
Total other income (expense), net, Q3 2026GAAP$62.24M––
Net income (loss), Q3 2026GAAP$54.86M––
Income attributable to participating warrants, Q3 2026GAAP−$12.22M––
Net income (loss) attributable to common stockholders, Q3 2026GAAP$42.64M––
Net income (loss) per share, basic, Q3 2026GAAP$1.15––
Net loss per share, diluted, Q3 2026GAAP$(0.24)––
Grant and award revenue, nine months ended Sep 30, 2026GAAP$6.47M––
Research and development expenses, nine months ended Sep 30, 2026GAAP20.53M––
General and administrative expenses, nine months ended Sep 30, 2026GAAP$12.42M––
Total operating expenses, nine months ended Sep 30, 2026GAAP$32.95M––
Operating loss, nine months ended Sep 30, 2026GAAP−$26.48M––
Interest income, nine months ended Sep 30, 2026GAAP$335K––
Interest expense, nine months ended Sep 30, 2026GAAP−$19.75M––
Change in fair value of the Convertible Loan, nine months ended Sep 30, 2026GAAP$59.55M––
Total other income (expense), net, nine months ended Sep 30, 2026GAAP$40.13M––
Net income (loss), nine months ended Sep 30, 2026GAAP$13.65M––
Income attributable to participating warrants, nine months ended Sep 30, 2026GAAP−$3.06M––
Net income (loss) attributable to common stockholders, nine months ended Sep 30, 2026GAAP$10.59M––
Net income (loss) per share, basic, nine months ended Sep 30, 2026GAAP$0.29––
Net loss per share, diluted, nine months ended Sep 30, 2026GAAP$(0.74)––
Net cash used in operating activities, nine months ended Sep 30, 2026GAAP−$19.96M––

Capital returns

  • The filing reports no share repurchases and no dividends.
  • Proceeds from issuance of common stock under the ATM, net, were $2,373 thousand for the nine months ended Sep 30, 2026 (nil for the nine months ended Sep 30, 2025).
  • Proceeds from exercise of stock options were $1,242 thousand for the nine months ended Sep 30, 2026 (nil in 2025).
  • Payments for taxes related to net share settlement of equity awards were $(121) thousand for the nine months ended Sep 30, 2026, compared with $(46) thousand in 2025.
  • Armata received $3.7 million in additional non-dilutive funding from the DoW. Cumulative non-dilutive DoW funding under the award is approximately $32.4 million, including $28.7 million previously provided.

What drove it

  • The company states that grant and award revenue of $3.2 million represents the Medical Technology Enterprise Consortium's share of the costs incurred for the AP-SA02 program for the treatment of SAB.
  • The company states that net income for the third quarter of 2026 was primarily driven by the gain of $69.6 million from the change in fair value of the convertible loan.
  • The company describes the AP-SA02 Phase 3 preparations as covering clinical, regulatory, manufacturing and operational work, including four engineering runs, one cGMP production run and vialing of drug product completed in Q3 2026, contracts with clinical research organizations, and clinical trial agreement negotiations with an initial group of U.S. clinical trial sites.
  • Interest expense rose to $(7,561) thousand in Q3 2026 from $(4,346) thousand in Q3 2025 as printed in the statement of operations.

Concerns

  • Net income in Q3 2026 depends on the $69.6 million gain from the change in fair value of the convertible loan. The statement of operations shows the operating loss of $(7,383) thousand separately.
  • Current liabilities rose to $186,778 thousand, with the Convertible Loan of $94,309 thousand and term debt of $83,862 thousand classified as current at Sep 30, 2026.
  • The stockholders' deficit was $(174,128) thousand at Sep 30, 2026.
  • Cash and cash equivalents were $18,317 thousand at Sep 30, 2026, against nine-month net cash used in operating activities of $(19,964) thousand.
  • Interest expense for the nine months was $(19,754) thousand, compared with $(11,756) thousand in the prior-year period.
  • Income attributable to participating warrants was $(12,219) thousand in Q3 2026, reducing net income to $42,638 thousand attributable to common stockholders. Diluted EPS is printed as $(0.24).

What to watch

  • Initiation of the Phase 3 superiority study of AP-SA02. The company expects initiation in the second half of 2026, with exact timing depending on when FDA concurs with the protocol.
  • The status of FDA discussions on the final study design, including the protocol revisions the company says it submitted in response to FDA feedback.
  • Whether the company provides a further non-dilutive DoW funding tranche under the existing award, which the filing describes as approximately $32.4 million cumulative.
  • Current liabilities and the classification of the Convertible Loan and term debt, which are printed as current at Sep 30, 2026.
  • Future fair value changes of the convertible loan, which drove the Q3 2026 and nine-month net income figures.
  • The company's cash position against operating cash use, given the filing's $18,317 thousand of cash and cash equivalents at Sep 30, 2026.

Balance sheet and cash flow

  • Cash and cash equivalents were $18,317 thousand at Sep 30, 2026, compared with $8,688 thousand at Dec 31, 2025. The filing describes this as approximately $18.3 million of unrestricted cash.
  • Restricted cash was $4,120 thousand at Sep 30, 2026. Cash, cash equivalents and restricted cash were $22,437 thousand at Sep 30, 2026, compared with $20,146 thousand at Sep 30, 2025.
  • Total assets were $84,478 thousand at Sep 30, 2026, compared with $76,882 thousand at Dec 31, 2025.
  • Total current liabilities were $186,778 thousand at Sep 30, 2026, compared with $8,947 thousand at Dec 31, 2025.
  • Convertible Loan, current was $94,309 thousand at Sep 30, 2026, and nil at Dec 31, 2025. Convertible Loan, non-current was nil at Sep 30, 2026, compared with $153,860 thousand at Dec 31, 2025.
  • Term debt, current was $83,862 thousand at Sep 30, 2026, and nil at Dec 31, 2025. Term debt, non-current was $43,299 thousand at Sep 30, 2026, compared with $103,061 thousand at Dec 31, 2025.
  • Total liabilities were $258,606 thousand at Sep 30, 2026, compared with $295,478 thousand at Dec 31, 2025.
  • Total stockholders' deficit was $(174,128) thousand at Sep 30, 2026, compared with $(218,596) thousand at Dec 31, 2025.
  • Nine-month net cash used in operating activities was $(19,964) thousand. Non-cash items in the reconciliation included change in fair value of the Convertible Loan of $(59,551) thousand and non-cash accrued interest expense of 19,740 thousand.
  • Nine-month purchases of property and equipment were $(171) thousand, compared with $(490) thousand in 2025. Net cash provided by financing activities was $28,494 thousand, compared with $24,954 thousand in 2025.
  • Proceeds from issuance of term debt, net of issuance costs, were $25,000 thousand in both nine-month periods.
  • As of Nov 6, 2026, 37,192,632 common shares were outstanding.

Analysis

Armata's Q3 2026 results combine a narrower operating loss with a headline net income that the company attributes to non-operating items. Grant and award revenue was $3,171 thousand in the quarter, against $1,159 thousand in Q3 2025, and the company describes this revenue as the Medical Technology Enterprise Consortium's share of AP-SA02 program costs. Research and development expenses were $6,830 thousand, against $5,824 thousand, and general and administrative expenses were $3,724 thousand, against $3,111 thousand. The operating loss was $(7,383) thousand, compared with $(7,776) thousand a year earlier. The filing presents no product revenue, and the company is a single-program business in the documents provided.

Below the operating line, the change in fair value of the convertible loan was a gain of $69,595 thousand in Q3 2026, against a loss of $(14,643) thousand in Q3 2025. Interest expense was $(7,561) thousand, against $(4,346) thousand. Total other income, net, was $62,240 thousand, which moved net income to $54,857 thousand from a net loss of $(26,675) thousand. The company states that net income for the quarter was primarily driven by the convertible loan gain. After income attributable to participating warrants of $(12,219) thousand, net income attributable to common stockholders was $42,638 thousand. The printed per-share figures are $1.15 basic and $(0.24) diluted, and the diluted figure is printed as a loss.

On a nine-month basis, operating loss widened to $(26,480) thousand from $(22,811) thousand, as R&D rose to 20,527 thousand from 17,647 thousand and G&A rose to 12,423 thousand from 8,983 thousand. Nine-month grant and award revenue was $6,470 thousand, against $3,819 thousand. Nine-month net income was $13,652 thousand, against a net loss of $(49,501) thousand, and nine-month operating cash use was $(19,964) thousand, against $(19,089) thousand. The company funded the period through $25,000 thousand of term debt proceeds (identical in both periods), $2,373 thousand of ATM proceeds, $1,242 thousand from option exercises, and cash of $18,317 thousand at period end.

The balance sheet is the main point of attention. Total liabilities were $258,606 thousand against total assets of $84,478 thousand, and the stockholders' deficit was $(174,128) thousand. The Convertible Loan of $94,309 thousand and term debt of $83,862 thousand are both classified as current at Sep 30, 2026, and current liabilities rose to $186,778 thousand from $8,947 thousand at Dec 31, 2025. The filing does not print a debt maturity schedule, so the reader should weigh the current classification against the cash balance directly. The company reports no share repurchases or dividends.

On outlook, the filing gives no financial guidance. Its operational guide is that the Phase 3 superiority study of AP-SA02 is expected to initiate in the second half of 2026, with timing dependent on FDA concurrence with the protocol. The company also cites Breakthrough Therapy designation, Fast Track and QIDP designations, an agreed Initial Pediatric Study Plan, and four engineering runs at its Los Angeles cGMP facility. The reader should set the clinical timeline against the current-debt classification and the operating cash use reported above.

Management, verbatim

We continue to advance toward our most important near-term objective: initiating the Phase 3 superiority study of AP-SA02.

Dr. Deborah Birx, Chief Executive Officer

Together, these accomplishments reflect the considerable effort and investment we have made to prepare for this important next stage of development, while maintaining fiscal discipline.

Dr. Deborah Birx, Chief Executive Officer

Not in the filing

stated, not guessed
  • Financial guidance for revenue, operating expenses, cash burn or net loss is not provided in the filing, and no prior-release outlook was supplied, so guidance and vs_prior_guidance are empty.
  • Year-over-year and quarter-over-quarter percentage changes are not printed for any line, so all change fields are null.
  • Quarter-over-quarter figures are not printed, because the filing presents only Q3 2026 and Q3 2025 for the quarter, and the nine-month columns for 2026 and 2025.
  • Operating cash flow for the quarter alone is not printed; only the nine-month figure is given.
  • Free cash flow is not printed and was not computed.
  • Non-GAAP measures are not presented in the filing.
  • The balance sheet compares Sep 30, 2026 with Dec 31, 2025, not with a prior-year quarter-end, so balance sheet items are given as text in balance_sheet_cash_flow and are not placed in prior_year fields.
  • Total debt is not printed as a single figure, and no total was computed from the convertible loan and term debt lines.
  • Debt maturity dates, interest rates and repayment terms are not printed in the filing.
  • Segment information is not presented, because the filing reports one revenue line (grant and award revenue) and no separate business or geographic breakdown.
  • The reason for the change in fair value of the convertible loan is not explained beyond its printed amount.
  • Share price reaction, analyst consensus and analyst expectations are not included in the filing.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Armata is a late‑stage biotech developing phage therapies for antibiotic‑resistant infections.

Company-level read

Ticker impact

$ARMPBullishHigh confidence
Context

Armata Pharmaceuticals filed an 8‑K reporting Q3 2026 results, FDA Breakthrough Therapy designation for AP‑SA02 and $3.7 M DoD funding for Phase 3 execution.

Expected impact

likely upward pressure as investors price in the breakthrough designation and funding support

Evidence & confidence

Breakthrough status accelerates review and signals strong clinical potential; fresh DoD money reduces cash‑burn concerns, prompting buying interest.

Market effects

Highlights growing investor interest in bacteriophage therapeutics and may boost related biotech peers.

U.S. biotech sector gains modest confidence from FDA breakthrough designations.

Limited to niche infectious‑disease biotech niche; no broad market effect.

Counterpoint

If Phase 3 enrollment delays or data fail to meet expectations, the breakthrough may not translate into near‑term price gains.

Key entities

  • Armata Pharmaceuticals, Inc.

    Developer of AP‑SA02 phage therapy for Staphylococcus aureus bacteremia.

  • U.S. Department of War

    Provider of $3.7 M non‑dilutive funding for Phase 3 execution.

  • FDA

    Granted Breakthrough Therapy designation to AP‑SA02.

Every ARMP earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$ARMPMed

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3…

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus ba

$ARMPMedAI 8/10

ARMP Stock Draws Bullish Focus After New Phage Breakthrough

Armata Pharmaceuticals Inc. (ARMP) stock rose 11.52% on September 14, 2026, driven by positive sentiment and a new peer-reviewed study on its therapeutic bacteriophage Ar-KM. The company's AP-PA02 therapy has completed Phase 2 trials, and the study provides mechanistic insights, reducing perceived development risk. Despite negative profitability and low revenue, traders are focused on the company's catalysts and momentum.